U.S. markets close in 5 hours
  • S&P 500

    4,554.89
    +9.99 (+0.22%)
     
  • Dow 30

    35,709.27
    +32.25 (+0.09%)
     
  • Nasdaq

    15,158.77
    +68.57 (+0.45%)
     
  • Russell 2000

    2,308.46
    +17.20 (+0.75%)
     
  • Crude Oil

    84.57
    +0.81 (+0.97%)
     
  • Gold

    1,808.70
    +12.40 (+0.69%)
     
  • Silver

    24.59
    +0.14 (+0.58%)
     
  • EUR/USD

    1.1616
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    1.6230
    -0.0320 (-1.93%)
     
  • GBP/USD

    1.3768
    +0.0009 (+0.07%)
     
  • USD/JPY

    113.6290
    +0.1690 (+0.15%)
     
  • BTC-USD

    63,333.81
    +3,203.85 (+5.33%)
     
  • CMC Crypto 200

    1,509.22
    +1,266.54 (+521.90%)
     
  • FTSE 100

    7,220.62
    +16.07 (+0.22%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FREMONT, Calif. and WALTHAM, Mass., May 25, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:30 p.m. ET.

Ardelyx logo (PRNewsFoto/Ardelyx) (PRNewsfoto/Ardelyx)
Ardelyx logo (PRNewsFoto/Ardelyx) (PRNewsfoto/Ardelyx)

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelyx, Inc.
Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2020. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2021-virtual-healthcare-conference-301298423.html

SOURCE Ardelyx